What it's for (Indications)
- Cinnarizine is indicated for the symptomatic treatment of vestibular disorders, including vertigo, tinnitus, nystagmus, nausea, and vomiting of labyrinthine origin, such as those associated with Ménière's disease and other forms of vestibular neuritis.
- It is also widely employed for the prevention of motion sickness, alleviating symptoms like nausea, vomiting, and dizziness experienced during travel.
- Beyond vestibular applications, cinnarizine has been utilized in the management of symptoms associated with cerebral circulatory disorders, such as headache of vascular origin, irritability, memory disturbances, and lack of concentration.
- Furthermore, it may be indicated for the treatment of symptoms related to peripheral circulatory disorders, including claudication, Raynaud's phenomenon, acrocyanosis, and trophic disturbances.
- The primary therapeutic focus remains on its anti-vertiginous and antiemetic properties stemming from its effects on the inner ear and central nervous system.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of cinnarizine must be individualized based on the patient's age, clinical condition, and the specific indication being treated. For the symptomatic treatment of vestibular disorders, such as vertigo or Ménière's disease, the typical adult dosage is 15-30 mg, administered two to three times daily. For the prevention of motion sickness, adults are generally advised to take an initial dose of 15-30 mg approximately two hours before travel, followed by 15 mg every eight hours during the journey if symptoms persist or are anticipated. For cerebral circulatory disorders, common adult dosing ranges from 25-75 mg daily in divided doses. In cases of peripheral circulatory disorders, adult dosages may range from 50-75 mg, two to three times daily. Pediatric dosages are significantly lower and should be determined by a healthcare professional based on age and weight. Dosage adjustments may be necessary in patients with hepatic or renal impairment. It is crucial to adhere strictly to the prescribed dosage and not to exceed the maximum recommended daily dose to minimize the risk of adverse effects and ensure optimal therapeutic outcomes. |
Safety & Warnings
Common Side Effects
- Cinnarizine is generally well-tolerated, but like all medications, it can cause adverse effects.
- The most frequently reported side effect is central nervous system depression, primarily manifested as drowsiness or sedation, which can significantly impair alertness and psychomotor performance, thus affecting the ability to drive or operate machinery.
- Other common adverse reactions include fatigue, gastrointestinal disturbances such as nausea, dyspepsia, or stomach discomfort, and headache.
- Less common but potentially serious side effects, especially with higher doses or prolonged use in susceptible individuals (e.
- g.
- , elderly), include extrapyramidal symptoms (EPS) like tremor, rigidity, akathisia, and tardive dyskinesia; these warrant immediate medical attention.
- Other reported side effects include dry mouth, weight gain, hyperhidrosis, skin reactions (e.
- g.
- , rash, pruritus), and very rarely, cholestatic jaundice or elevation of liver enzymes.
- Patients should be advised to report any persistent or bothersome side effects to their healthcare provider for evaluation and potential management.
Serious Warnings
- Black Box Warning: While Cinnarizine does not carry a formal FDA Black Box Warning, clinicians and patients must be cognizant of several serious risks associated with its use, particularly given its potential for severe neurological and central nervous system effects. A significant concern, especially in elderly individuals or those on prolonged therapy, is the development or exacerbation of extrapyramidal symptoms (EPS), including tremor, rigidity, bradykinesia, akathisia, and tardive dyskinesia. This risk necessitates careful monitoring, especially in patients with pre-existing neurological conditions or those predisposed to movement disorders. Patients with Parkinson's disease should generally avoid cinnarizine due to the high potential for exacerbation of their motor symptoms and drug-induced parkinsonism. Furthermore, cinnarizine can cause significant central nervous system depression, leading to profound drowsiness, sedation, and impaired psychomotor function, which can severely affect the ability to operate machinery or drive safely. Concomitant use with other CNS depressants, including alcohol, sedatives, hypnotics, and opioid analgesics, can dangerously potentiate these sedative effects, potentially leading to respiratory depression or profound somnolence. Healthcare providers should ensure patients are fully informed of these risks prior to initiating therapy.
- Cinnarizine can cause significant central nervous system depression, leading to drowsiness, sedation, and impaired psychomotor function.
- Patients should be warned against operating heavy machinery or driving while under the influence of this medication.
- Concomitant use with other CNS depressants, such as alcohol, sedatives, hypnotics, or opioid analgesics, can potentiate these effects, leading to profound sedation or respiratory depression.
- Caution is advised in patients with a history of epilepsy, as cinnarizine may lower the seizure threshold.
- Patients with Parkinson's disease should generally avoid cinnarizine due to the potential for exacerbation of their symptoms or induction of drug-induced parkinsonism.
- It should be used with caution in patients with hepatic or renal impairment, and dose adjustments may be necessary.
- Prolonged use, especially in the elderly, increases the risk of extrapyramidal symptoms.
- Discontinuation should be gradual if prolonged use has occurred to prevent potential withdrawal effects.
- The drug should also be used with caution in patients with hypotension or prostate hypertrophy.
How it Works (Mechanism of Action)
Cinnarizine exerts its therapeutic effects through a multifaceted mechanism of action, primarily as a selective calcium channel antagonist and an H1-antihistamine. It acts to inhibit the influx of calcium ions into depolarized vascular smooth muscle cells, particularly within cerebral and peripheral arterioles. This calcium channel blocking activity leads to vasodilation, thereby improving microcirculatory blood flow, which is beneficial in conditions of cerebral and peripheral circulatory insufficiency by enhancing oxygen and nutrient supply to tissues. In the vestibular system, cinnarizine's calcium antagonistic properties reduce the excitability of the vestibular labyrinth, diminishing the activity of the hair cells in the inner ear. This action helps to suppress nystagmus, vertigo, and other symptoms associated with vestibular dysfunction and motion sickness. Furthermore, its antihistaminic (H1-receptor blocking) properties contribute to its antiemetic and sedative effects, alleviating nausea and vomiting. The combination of these pharmacological actions makes cinnarizine effective in managing a range of vestibular and circulatory disorders.